RU2011137413A - Применение кардиотрофина-1 для лечения метаболических заболеваний - Google Patents

Применение кардиотрофина-1 для лечения метаболических заболеваний Download PDF

Info

Publication number
RU2011137413A
RU2011137413A RU2011137413/15A RU2011137413A RU2011137413A RU 2011137413 A RU2011137413 A RU 2011137413A RU 2011137413/15 A RU2011137413/15 A RU 2011137413/15A RU 2011137413 A RU2011137413 A RU 2011137413A RU 2011137413 A RU2011137413 A RU 2011137413A
Authority
RU
Russia
Prior art keywords
cardiotrophin
compound
functionally equivalent
activity
equivalent variant
Prior art date
Application number
RU2011137413/15A
Other languages
English (en)
Russian (ru)
Inventor
Вальтуэнья Хесус Мария Прьето
ДЕ АБАХО Матильде БУСТОС
АЛИАГА Мария Хесус МОРЕНО
Original Assignee
Проекто Де Биомедисина Сима, С.Л.
Институто Сьентифико И Текнолохико Де Наварра, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проекто Де Биомедисина Сима, С.Л., Институто Сьентифико И Текнолохико Де Наварра, С.А. filed Critical Проекто Де Биомедисина Сима, С.Л.
Publication of RU2011137413A publication Critical patent/RU2011137413A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2011137413/15A 2009-02-12 2010-02-10 Применение кардиотрофина-1 для лечения метаболических заболеваний RU2011137413A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200900396 2009-02-12
ES200900396 2009-02-12
PCT/ES2010/070072 WO2010092218A2 (es) 2009-02-12 2010-02-10 Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas

Publications (1)

Publication Number Publication Date
RU2011137413A true RU2011137413A (ru) 2013-03-20

Family

ID=42562119

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011137413/15A RU2011137413A (ru) 2009-02-12 2010-02-10 Применение кардиотрофина-1 для лечения метаболических заболеваний

Country Status (11)

Country Link
US (1) US20110293562A1 (enExample)
EP (1) EP2397152B1 (enExample)
JP (1) JP2012517459A (enExample)
CN (1) CN102316892B (enExample)
AU (1) AU2010212794A1 (enExample)
BR (1) BRPI1008415A2 (enExample)
CA (1) CA2750074A1 (enExample)
ES (1) ES2493618T3 (enExample)
MX (1) MX2011008562A (enExample)
RU (1) RU2011137413A (enExample)
WO (1) WO2010092218A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419916B2 (en) 2012-09-11 2022-08-23 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
EP3110946B1 (en) * 2014-02-24 2021-09-01 Energesis Pharmaceuticals Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
EP0179904A1 (en) 1984-05-09 1986-05-07 Medaphore Inc. Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
AU2329199A (en) 1998-01-29 1999-08-16 Poly-Med, Inc. Absorbable microparticles
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
EP1539930A4 (en) * 2002-07-29 2006-08-09 Es Cell Int Pte Ltd METHOD IN MULTIPLE STAGES OF DIFFERENTIATION OF POSITIVE INSULIN-SENSITIVE CELLS, GLUCOSE
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
WO2006097526A1 (en) * 2005-03-17 2006-09-21 Novo Nordisk A/S Compounds for use in the treatment of obesity
AU2007214708A1 (en) 2006-02-15 2007-08-23 Sanofi-Aventis Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments

Also Published As

Publication number Publication date
JP2012517459A (ja) 2012-08-02
CN102316892A (zh) 2012-01-11
MX2011008562A (es) 2011-09-09
WO2010092218A3 (es) 2010-11-18
WO2010092218A2 (es) 2010-08-19
ES2493618T3 (es) 2014-09-12
BRPI1008415A2 (pt) 2018-02-27
CN102316892B (zh) 2014-06-04
AU2010212794A1 (en) 2011-08-11
CA2750074A1 (en) 2010-08-19
EP2397152B1 (en) 2014-05-28
US20110293562A1 (en) 2011-12-01
EP2397152A2 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
CN104981240B (zh) 通过控制血糖水平用于治疗糖尿病及相关病症的组合物、方法以及用途
RU2017146048A (ru) Композиции инсулинов длительного действия
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
JP2015143253A5 (enExample)
JP2011241213A5 (enExample)
JP2014520864A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
ME01546B (me) Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2
ZA202309366B (en) Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
JP2022512843A5 (enExample)
CN105853421A (zh) FoxO1选择性抑制剂AS1842856的新用途
JP2012517459A5 (enExample)
CN101966191A (zh) 一种治疗高血压含氨氯地平和替米沙坦的复方制剂
CN114712482B (zh) 一种含虾青素的洁阴抑菌凝胶及其制备方法
CN106265713A (zh) 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物
CN109793740A (zh) 盐酸帕唑帕尼在制备治疗肺纤维化疾病药物中的应用
JP2022507646A (ja) ブレイアコニチンａの用途
CA2750074A1 (en) Use of cardiotrophin-1 for the treatment of metabolic diseases
CN109498599A (zh) 日常保健缓释凝胶药膏片
CN105056063B (zh) 一种中药组合物
CO2023002829A2 (es) Formulación compuesta para tratamiento de diabetes mellitus tipo 2
CN102391160A (zh) 二甲双胍与2，5-二羟基苯磺酸盐以及二甲双胍与2，5-二羟基苯磺酸盐的复方组合物
CN103860578A (zh) 香菇多糖作为抗抑郁症药物的用途
WO2018219033A1 (zh) 一种2型糖尿病的多药联用康复冲剂及其应用
CN105311387B (zh) 复方手参丸在制备治疗原发性震颤药物中的应用